SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yeh TC, Liu HC, Wang LY, Chen SH, Liang DC. Invasive fungal infection in children undergoing chemotherapy for cancer. Ann Trop Paediatr. 2007;27:141-147.
  • 2
    Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055-2061.
  • 3
    Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113:376-382.
  • 4
    Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer. 2009;53:605-609.
  • 5
    Doring M, Muller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012;12:263.
  • 6
    Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:397-405.
  • 7
    Liang DC, Chang TT, Lin KH, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia. 2006;20:136-141.
  • 8
    van Burik JA, Ratanatharathorn V, Stepan DE, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407-1416.
  • 9
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-140.
  • 10
    De Pauw BD, Walsh TJ, Donnelly JP, et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
  • 11
    Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf, 2009. Accessed January 3, 2014.
  • 12
    Wingard JR, Carter SL, Walsh TJ, et al; Blood and Marrow Transplant Clinical Trials Network. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111-5118.
  • 13
    Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-1552.
  • 14
    Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 1993;53:5121-5126.
  • 15
    Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412-415.
  • 16
    Lo WT, Lin WJ, Chiueh TS, Lee SY, Wang CC, Lu JJ. Changing trends in antimicrobial resistance of major bacterial pathogens, 1985-2005: a study from a medical center in northern Taiwan. J Microbiol Immunol Infect. 2011;44:131-138.
  • 17
    Livermore DM, James D, Reacher M, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis. 2002;8:473-478.
  • 18
    Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56:2181-2183.
  • 19
    Kuse ER, Chetchotisakd P, da Cunha CA, et al; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.
  • 20
    Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
  • 21
    Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16:180-186.
  • 22
    Queiroz-Telles F, Berezin E, Leverger G, et al; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820-826.